Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1078 in advanced solid tumors
NCT06771921Phase 2Terminated
- Sponsor
- Genmab
- Start
- Jan 2025
- Primary completion
- Jun 2025
- Modality
- Bispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of GEN1078 in malignant solid tumor (2 arms), sponsored by Genmab. Primary endpoints: Dose-limiting Toxicities at 21 days, Adverse Events and 1 more. Started Jan 2025; status: terminated.
02
Drugs
GEN1078
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06771921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06771921.